41 results about "Urine cells" patented technology

The present invention relates to a method of increasing the yield of cells collected in a urine sample comprising the steps of applying energy wave forms to a bladder wherein the energy loosens cells attached to the inner lining of the bladder, and collecting urine sample containing the loosened cells.

The invention provides a method for preparing cartilage tissues from artificial in-vitro sources by the aid of human urine cells in an in-vitro manner. The method includes steps of (1), a), reprogramming the human urine cells to generate induced pluripotent stem cells and directionally differentiating the induced pluripotent stem cells to obtain mesenchymal stem cells, or b), carrying out transdifferentiation to generate the mesenchymal stem cells; (2), cultivating the mesenchymal stem cells obtained at the step (1) in cartilage induced differentiation media to obtain the cartilage tissues from the artificial in-vitro sources. The method has the advantages that the cartilage tissues are constructed in the in-vitro manner and can be used for replacing damaged or lesion tissue cells, so that the purpose of repairing cartilage can be achieved, and the effective method is provided for constructing the cartilage tissues in the in-vitro manner and has huge application value.

The invention belongs to the biotechnical field and in particular to tissue engineering skin containing appendage and a preparation method thereof. The preparation method comprises the following steps: performing transfection of a urine cell to induce to generate a multifunctional stem cell; continuously inducing the multifunctional stem cell to generate a mesenchymal stem cell; differentiating the mesenchymal stem cell to form an epidermis cell, a fibroblast and a hair follicle cell; and constructing tissue engineering double-layered skin containing the appendage with a biological stent material amniotic membrane. The seed cell of the tissue engineering skin prepared by the preparation method is the urine cell which is convenient to obtain and short in cultivation period. The hair follicle structure which is contains facilitates union of a wound, and the tissue engineering skin containing the appendage provided by the invention lays a foundation for follow-up development of the tissue engineering skin containing the appendage.

The invention relates to the field of cell pathology detection, in particular to a method of extraction and flaking of body fluid cells for checking bladder cancer. The extraction method comprises a sampling process and a treatment process. According to the method of extraction of body fluid cells for checking bladder cancer, urine sediment is broken and decomposed without damage, the problems that urine cells cannot be stored for a long time and the quantity of the cells is small due to the fact that the urine is autolyzed after leaving the human body for 2 hours are solved, the urine samplecan be stored for 7-10 days, the problem that the inspection turnover time is not enough is thoroughly solved, and the non-invasive detection can really benefit the public. The first morning urine with the most abundant diagnostic information and the most urinary sediments is adopted so that exfoliated cells can be completely dissociated from the urinary sediments, more than 5000 cells can be collected from the first morning urine and the sampling quantity, quality and detection success rate are greatly improved.

The invention provides a method for culturing human induced pluripotent stem cells by using human urine cells as a feed layer. Third-twelfth generations of human urine cells cultured after subculture,cryopreservation and resuscitation are used as trophoblast cells for culturing the human induced pluripotent stem (hiPS) cells reassembled by adult male foreskin fibroblasts. The used human urine cells replace small mouse embryo fibroblasts or mouse embryo fibroblast cell lines used in traditional methods, the human induced pluripotent stem cells are cultured, pollution of heterologous cells in the culture system is reduced, and the human induced pluripotent stem cells are more easily obtained than mesenchymal stem cells. The culture system is proved to make the human induced pluripotent stemcells amplified in vitro, the biological characteristics and the pluripotent property of the hiPS cells are maintained for a long time, and the possibility is provided for the hiPS to enter the clinical application.

The invention provides a preparation method of high-mutation urine stem cells in mitochondria mt.3243A > G mutation crowds. The method comprises the following steps: collecting urine cells of mitochondria mt.3243A > G mutant population; obtaining a sediment red tube by adopting a mode of centrifuging and adding a PBS to blow, beat and mix uniformly, obtaining P1-generation high-mutation urine stemcells are obtained, and obtaining the mitochondria mt.3243A > G mutation urine stem cells with the high mutation rate of 95% or above through digestion passage and mutation rate detection. The methodhas the advantages that the method can be obtained in a non-invasive mode, and the method can be obtained regardless of the gender, age and health condition of the patient. As a primary cell, the cell line maintains the basic properties of the original cell. The invention provides a cell application platform for researching the pathogenesis of mt.3243A > G mutant cells in the future and screeningnew drugs aiming at mt.3243A > G.

The invention relates to the technical field of stem cells and genetic engineering, in particular to a culture medium and application thereof and a method for preparing mesenchyme stem cells through urine cells. According to the method capable of inducing the urine cells to become the mesenchyme stem cells in the culture medium, the urine cells are wide in source, and are not limited by ethic, and through the adoption of the method, the urine cells form IPS cells embryoid bodies-mesenchyme stem cells in sequence. All induction can be completed in 20-25 days, and the obtained cells conform to characteristics of the mesenchyme stem cells after being detected, are large in quantity, and high in motility rate.

The invention relates to a human induced pluripotent stem cell strain SXMUi002-A-1. The human induced pluripotent stem cell strain SXMUi002-A-1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human induced pluripotent stem cell strain SXMUi002-A-1 is CGMCC No: 22359. The iPSC is obtained by extracting urine cells from urine of a B-type hemophilia patient carrying F9c.223C>T(p.R75X) nonsense mutation and reprogramming, and further research finds that the iPSC is similar to an embryonic stem cell in the aspects of cellular morphology, gene expression, proliferation and differentiation potential and has the potential of differentiating to three germ layers. The prepared human induced pluripotent stem cell strain SXMUi002-A-1 has important value for molecular mechanism research of hemophilia nonsense mutation, hemophilia detection, drug screening, gene therapy and other clinical application researches, and provides important resources.

The invention discloses BTHS inducible multi-functional stem cells, a preparation method thereof, a differential culture medium and a purpose. The preparation method comprises the steps of taking 150-200 milliliters of urine of a BTHS patient, and performing centrifugation at 2000 revolution per minute for 10 minutes to obtain urine cells; after the cells are counted, with the quantity of 3.5-4*10<5>, performing inoculation to a 6-hole culture board in which matrigel is incubated at 37 DEG C for an hour or above; after passage, culturing third-generation urine cells to reach 80% of convergence, infecting sendai viruses containing four transcription factors of OCT4, SOX2, KLF4 and c-MYC, and performing reprogramming induction; after 15 days of viral infection, starting to generate clone regiment like cells, through manually selecting clone regiment cells, performing transferring to a new 24-hole culture board in which the matrigel is incubated, and performing culture; and after repeatedpassage, completing multiple index identification, so as to obtain purified iPS cell lines (TAZ-UiPSC) having a BTHS patient urine cell source. The TAZ-UiPSC can be directionally induced and differentiated into cardiac muscle cells to establish an in vitro cell model, and is used for researching of BTHS pathogenic mechanisms and screening of targeted medicines.

The invention discloses a chip suitable for separating and analyzing urine cells and other visible components and an auxiliary reagent. The chip comprises the auxiliary reagent, which is a chemical mixed solution with sucrose concentration ranging from 5 to 50 percent and a buffer pH value of 7.4. The chip comprises a chip baseplate, a separation chip structure for storing urine, urine cells and other visible components in the chip, and a visible component separation buffer solution chip; and the outer part of the chip is linked with urine visible component collectors. 1. The chip for measuring urine cells and other visible components is characterized in that a chip auxiliary reagent skill storage chip is arranged outside a urine storage chip, and the framework of the chip is closely combined with the bottom cover and the upper cover of the chip. 2. The chip for separating urine cells and other visible components, as described in Claim 1 is characterized in that the urine storage chip and the separation solution chip both adopt a circular structure, four notches are formed in the framework of each chip, closely packed rubber isolating layers are arranged at the peripheries of the frameworks of the urine storage chip and the visible component separation solution chip, each rubber isolating layer is also provided with four notches, and after the rubber isolating layers are turned to superpose the notches, urine cells and other visible components can pass through the notches.

The invention relates to the technical field of biomedicine, and particularly discloses a non-gynecological exfoliated cell preserving fluid, a kit containing the preserving fluid and application. The non-gynecological exfoliated cell preserving fluid is prepared from the following components in percentage by weight: 17-25% of a fixing agent, 2.5-3.5% of glycerol; 1.2%-1.5% of a hemolytic agent; 3.5%-4.5% of an anticoagulant; 0.2-0.4% of sodium chloride; and the balance of deionized water. The fixing agent comprises at least one of ethanol and methanol; the hemolytic agent is prepared from ammonium sulfate, trihydroxymethyl aminomethane and sodium salt; the preparation method comprises the following steps: uniformly mixing the deionized water, the anticoagulant, the sodium chloride and the glycerol, and then uniformly mixing the mixture with the fixing agent and the hemolytic agent to obtain the non-gynecological exfoliated cell preserving fluid. The kit containing the preserving fluid further comprises a diluent and an adhesive slide, the kit is applied to sputum cell series, needle suction and endoscope series, serous cavity effusion series and urine cell series. The preserving fluid has the capability of removing red blood cells.

The invention discloses a method for capturing and detecting abnormal metabolic cells in urine. The method comprises the following steps: removing sample impurities; to be specific, taking a urine sample, pouring the urine sample into a test tube, then adding a urease aqueous solution into the test tube, carrying out standing and incubating to remove urea in the urine sample, then adding an activeadsorbent, and removing sulfur and phosphorus in the urine sample by using ultrasonic oscillation; and adding a PBS solution; to be specific, pouring the urine sample into centrifugal equipment for centrifuging, and adding the PBS solution to obtain FPBS resuspended urine cells. According to the method, the technological processes of removing sample impurities, adding a PBS solution, treating a vessel, pouring into the vessel and detecting are set and thus problems that the settling velocity difference is large caused by different viscosities and thus images are not clear and the detection result is inaccurate according to the existing cell capturing and detecting method are solved. The method for capturing and detecting abnormal metabolic cells in urine has advantages of being clear in image and accurate in detection result.

The invention discloses a urine cell collection vehicle comprising a vehicle body and a support frame; the support frame is positioned on the lower side of the vehicle body and is used for supportingthe vehicle body. The vehicle body comprises a cab and a compartment, and an opening with a movable door is formed in the side wall of the compartment. A centrifugal separator, a clean working table,a refrigerator, a storage cabinet and a folded workbench located on the inner side wall are arranged in the compartment, an air conditioner with an ozone generator is arranged at the top of the compartment, a new fan is arranged at the bottom of the compartment, and an ultraviolet disinfection lamp and an illuminating lamp are arranged on the inner wall of the compartment. The urine cell collection vehicle can meet the equipment requirements for preliminary processing and extraction of urine cells, also, various related reagents and extracted cells can be stored at a low temperature by using the refrigerator, and mobile urine collection and storage places can be provided through the mobile vehicle body. Meanwhile, a novel fan and an air conditioner with an ozone generator are further arranged, so that the operation environment inside the compartment is guaranteed. The urine cell collection vehicle in the invention is applied to the field of medical sampling.

The present invention relates to endothelial and smooth muscle-like vascular tissues produced from urine cells. In certain embodiments, the present invention relates to methods of producing endothelium and smooth muscle-like vascular tissue by exposing urine-derived cells containing ETV2 to a first growth medium under conditions such that the cells are modified to form a cell pool with increased expression level of endothelial surface markers, and then separating the cells from the first growth medium. The cell pool is exposed to a second growth medium under conditions such that cells, which have increased smooth muscle surface marker expression levels in addition to endothelial cell surface markers, are modified to form a cell-containing tissue. In certain embodiments, the invention relates to the treatment of vascular, cardiac and wound healing related symptoms using the cells and tissues reported herein.

A method for inducing reprogramming of neural stem cells from urine cells by introducing mRNAs of reprogramming factors Oct4, Sox2, Klf4, and Glis1 is disclosed. A composition for the prevention or treatment of neurological damage diseases with the neural stem cells induced by the method as an active ingredient is disclosed.

The present invention relates to a method for inducing reprogramming of urine cells into keratinocyte stem cells by introducing reprogramming factors Bmi1 and dNP63a, and a composition for promoting skin regeneration which includes an induced reprogrammed keratinocyte stem cell conditioned medium as an active ingredient.

The invention discloses a specific induced pluripotent stem cell line containing CLCN2 homozygous mutation (c.2257C>T) for leukoencephalopathy patients. Urine of a patient with CLCN2 gene mutation iscollected, urine cells are separated and cultured, and the urine cells are reprogrammed into induced pluripotent stem cells to obtain the specific induced pluripotent stem cell line containing CLCN2 homozygous mutation (c.2257C>T) for leukoencephalopathy patients. The STR of the induced pluripotent stem cells is the same as that of the CLCN2 patient, and the induced pluripotent stem cells expressea pluripotent molecular tag, have ability of forming teratoma in vivo, and can provide a new biological material and a cell model tool for pathogenesis and treatment research of CLCN2 mutation related diseases.